血管内皮生长因子基因多态性与乳腺癌关系的研究进展

doi:10.11904/j.issn.1002-3070.2016.03.019

摘要/Abstract

摘要： 血管内皮生长因子(VEGF)作为血管生成的关键要素,其基因的多态性可能会影响乳腺癌的发生、发展和预后,从基因多态性的角度来研究乳腺癌的预后以及抗VEGF药物的疗效具有重要意义。因此,本文就VEGF基因的多态性与乳腺癌关系的研究进展做一综述。

关键词: 血管内皮生长因子, 基因多态性, 乳腺癌

Abstract: Vascular endothelial growth factor(VEGF),as a critical factor in angiogenesis,its polymorphisms may influence the occurrence,development and prognosis of breast cancer.With the perspective of gene polymorphism,the prediction in the prognosis of breast cancer and the therapeutic effect of anti-VEGF drugs is of great significance.Therefore,the relations of VEGF gene polymorphism and breast cancer were summarized in this paper.

Key words: Vascular endothelial growth factor, Gene polymorphisms, Breast cancer

中图分类号:

R737.9

陈龙综述, 钱诚审校. 血管内皮生长因子基因多态性与乳腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 284-286.

CHEN Long,QIAN Cheng. Research advances on the relations of vascular endothelial growth factor polymorphisms and breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(3): 284-286.

参考文献

1 汪春林,黄盛鑫,程小伟,等.VEGF+936+C/T多态性与乳腺癌易感性关系的分析[J].肿瘤防治研究,2013,40(5):489-494.
2 Wang Z,Dabrosin C,Yin X,et al.Broad targeting of angiogenesis for cancer prevention and therapy[J].Seminars in Cancer Biology,2015,35(Suppl)224-243.
3 Arcondeguy T,Lacazette E,Millevoi S,et al.VEGF-A mRNA processing,stability and translation:a paradigm for intricate regulation of gene expression at the post-transcriptional level[J].Nucleic Acids Res,2013,41(17):7997-8010.
4 Koutras A,Kotoula V,Fountzilas G,et al.Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer[J].Pharmacogenomics,2015,16(1):79-94.
5 Gianni L,Chan A,Mansutti M,et al.Biomarker(BM)results from the Phase III AVEREL trial of 1st-line bevacizumab(BV),trastuzumab(H)+docetaxel(T)for HER-2-positive locally recurrent/metastatic breast cancer(LR/mBC)[J].Ann Oncol,2012,(23):1657-1663.
6 Van Cutsem E,Jayson G,Dive C,et al.Analysis of blood plasma factors in the AVITA Phase III randomized study of bevacizumab(bev)with gemcitabine-erlotinib(GE)in patients(pts)with metastatic pancreatic cancer(mPC)[J].European Multidisciplinary Cancer Congress Stockholm,2011,(9):803-811.
7 Van Cutsem E,De Haas S,Kang YK,et al.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:a biomarker evaluation from the AVAGAST randomized Phase III trial[J].J Clin Oncol,2012,30(17):2119-2127.
8 Miles DW,De Haas SL,Dirix LY,et al.Biomarker results from the AVADO Phase 3 trial of first-line bevacizumab plus docetaxel for HER-2-negative metastatic breast cancer[J].Br J Cancer,2013,108(5):1052-1060.
9 Lambrechts D,Moisse M,Delmar P,et al.Genetic markers of bevacizumab-induced hypertension[J].Angiogenesis,2014,(17):685-694.
10 Luo T,Chen L,He P,et al.Vascular endothelial growth factor(VEGF)gene polymorphisms and breast cancer risk in a Chinese population[J].Asian Pac J Cancer Prev,2013,14(4):2433-2437.
11 Jain L,Vargo CA,Danesi R,et al.The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors[J].Mol Cancer Ther,2009,(8):2496-2508.
12 柏立婧,杨宝山.VEGF-634G/C基因多态性与疾病相关性的研究进展[J].世界华人消化杂志,2014,22(13):1801-1805.
13 Eng L,Azad AK,Habbous S,et al.Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer:a systematic review and meta-analysis[J].Clin Cancer Res,2012,18(17):4526-4537.
14 Krippl P,Langsenlehner U,Renner W,et al.A common 936C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk[J].Int J Cancer,2003,106(4),468-471.
15 Rodrigues P,Furriol J,Tormo E,et al.The single nucleotide polymorphisms +936 C/T VEGF and-710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population[J].Breast Cancer Res Treat,2012,133(2):769-778.
16 Yan Y,Liang H,Li T,et al.Vascular endothelial growth factor +936C/T polymorphism and breast cancer risk:a meta-analysis of 13 case-control studies[J].Tumor Biol,2014,35(3):2687-2692.
17 Oliveira C,Lourenco GJ,Silva PM,et al.Polymorphisms in the 5′-and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics[J].Tumor Biol,2011,32(2):295-300.
18 Yang DS,Park KH,Woo OH,et al.Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk:a meta-analysis[J].Breast Cancer Res Treat,2011,125(3):849-853.
19 Renner W,Kotschan S,Hoffinann C,et al.A common 936C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels[J].Vase Res,2000,28(37):443-448.
20 Langsenlehner U,Hofmann G,Renner W,et al.Association of vascular endothelial growth factor—a gene polymorphisms and haplotypes with breast cancer[J].Acta Oncol,2015,54(3):368-376.
21 Etienne-Grimaldi MC,Formento P,Degeorges A,et al.Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients[J].Br J Clin Pharmacol,2011,71(6):921-928.
22 汪春林.血管内皮生长因子基因多态性与恶性肿瘤的研究进展[J].中国肿瘤临床,2012,39(24):1117-1120.
23 Jacobs EJ,Feigelson HS,Bain EB,et al.Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort[J].Breast Cancer Res,2006,8(2):22-31.
24 Schneider BP,Wang M,Radovich M,et al.Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer:ECOG 2100[J].Clin Oncol,2008,26(28):4672-4678.
25 Cao C,Ying T,Fang JJ,et al.Polymorphism of vascular endothelial growth factor-2578C/A with cancer risk:evidence from 11263 subjects[J].Med Oncol,2011,28(4):1169-1175.
26 Kidd LR,Brock GN,Vancleave TT,et al.Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival[J].Cancer Causes Control,2010,21(10):1545-1557.
27 Kim YR,Hong SH.The protective effects of the VEGF-2578C＞A and-1154G＞A polymorphisms against hypertension susceptibility[J].Genet Test Mol Biomarkers,2015,19(9):476-480.
28 Song GG,Kim JH,Lee YH,et al.Vascular endothelial growth factor gene polymorphisms and vasculitis susceptibility:A meta-analysis[J].Hum Immunol,2014,75(6):541-548.
29 Sa-Nguanraksa D,Kooptiwut S,Chuangsuwanich T,et al.Vascular endothelial growth factor polymorphisms affect gene expression and tumor aggressiveness in patients with breast cancer[J].Mol Med Rep,2014,9(3):1044-1048.
30 Lu H,Shu XO,Cui Y,et al.Association of genetic polymorphisms in the VEGF gene with breast cancer survival[J].Cancer Res,2005,65(12):5015-5019.
31 Koutras AK,Kotoula V,Papadimitriou C,et al.Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel[J].Pharmacogenomics J,2014,14(3):248-255.
32 Sa-Nguanraksa D,Chuangsuwanich T,Pongpruttipan T,et al.Vascular endothelial growth factor 634G/C polymorphism is associated with increased breast cancer risk and aggressiveness[J].Mol Med Rep,2013,8(4):1242-1250.
33 Maae E,Andersen RF,Steffensen KD,et al.Prognostic impact of VEGFA germline polymorphisms in patients with HER-2-positive primary breast cancer[J].Anticancer Res,2012,32(9):3619-3627.
34 Liu L,Zeng F,Wang K,et al.Meta-analysis of the association between VEGF-634 G＞C and risk of malignancy based on 23 case-control studies[J].Cancer Res Clin Oncol,2011,137(6):1027-1036.
35 Rani J,Rahul B,Ramesh G,et al.Association of vascular endothelial growth factor single nucleotide polymorphisms on the prognosis of breast cancer patients[J].Indian J Cancer,2014,51(4):512-517.
36 Balasubramanian SP,Cox A,Cross SS,et al.Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity[J].Int J Cancer,2007,121(5):1009-1016.
37 Lambrechts D,Lenz HJ,De Haas S,et al.Markers of response for the antiangiogenic agent bevacizumab[J].J Clin a Oncol,2013,31(9):1219-1230.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[5]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[6]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[7]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[8]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[9]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[10]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[11]	李响, 刘铎, 吴东媛, 范晓凡, 张娟, 董梅. 卡培他滨相关基因多态性与手足综合征关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 149-153.
[12]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[13]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.
[14]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[15]	陈琢, 孔艺然. 沉默UHRF1对乳腺癌细胞增殖和转移的影响[J]. 实用肿瘤学杂志, 2017, 31(6): 512-518.